Is this Patient with Metastatic Bladder Cancer a Candidate for Second-Line Immunotherapy Treatment?
Bourlon, M.ía.T.; Velázquez, H.E.; Luna-Santiago, R.; Vázquez-Manjarrez, S.; Bourlon, C.
Oncology 32(2): 64-68
2018
ISSN/ISBN: 0890-9091 PMID: 29492946 Document Number: 695441
Document emailed within 1 workday
Related Documents
Rissanen, A.-M.; Pekonen, M.; Terho, R.; Krees, R.; Katila, M.-L. 2002: Enlarged pelvic lymph nodes after immunotherapy in a patient with bladder cancer Duodecim; Laaketieteellinen Aikakauskirja 118(10): 1029-1032Rizvi, N.A. 2017: The use of immunotherapy in the first-line treatment of lung cancer Clinical Advances in Hematology and Oncology: H&o 15(3): 190-192
Lee, J.J.; Sun, W. 2016: Options for Second-Line Treatment in Metastatic Colorectal Cancer Clinical Advances in Hematology and Oncology: H&o 14(1): 46-54
Baltali, Eşmen.; Altundağ, M.Kadri.; Güler, Nüfer.; Ozişik, Y.; Firat, Dçer.; Baran, I.; Tekuzman, Gülten. 2002: Paclitaxel and doxorubicin combination in the first-line treatment of metastatic breast cancer Tumori 88(3): 200-203
2013: Danitumumab adjunctive therapy. No place in either first- or second-line treatment of metastatic colorectal cancer Prescrire International 22(138): 120
Moro-Sibilot, D.; Coudurier, M. 2009: Targeted therapies in second line treatment of metastatic non-small cell lung cancer La Revue du Praticien 59(7): 955-956
Karacetin, D.; Yalcin, B.; Okten, B.; Ozturk, S.; Maral, O.; Incekara, O. 2009: Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer Journal of BUON: Official Journal of the Balkan Union of Oncology 14(4): 605-608
Lück, H.J.; Thomssen, C.; du Bois, A.; Lisboa, B.W.; Untch, M.; Kühnle, H.; Jänicke, F.; Meerpohl, H.G.; Lindner, C.; Konecny, G.; Hecker, D.; Diergarten, K. 1997: Preliminary results of a phase Ii study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer Seminars in Oncology 24(1 Suppl 3: S13-S16
Négrier, S.; Mercatello, A.; Coronel, B.; Merrouche, Y.; Bret, M.; Blay, J.Y.; Thiesse, P.; Clavel, M.; Moskovtchenko, J.F.; Philip, T. 1993: Immunotherapy of metastatic kidney cancer Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 3(2): 187-194
Lüftner, D.; Pollmann, D.; Schildhauer, S.; Sehouli, J.; Possinger, K. 2005: Perspectives of immunotherapy in metastatic breast cancer Anticancer Research 25(6c): 4599-4604
Schmitz-Dräger, B.J.; Schattka, S.O.; Ebert, T. 1993: Immunotherapy of superficial bladder cancer Der Urologe. Ausg. a 32(5): 374-381
Saif, M.Wasif. 2013: U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer Jop: Journal of the Pancreas 14(6): 686-688
Lepistö, A.; Kouri, M.; Savolainen, R.; Ristimäki, A. 2016: What will determine the first-line treatment of a patient with rectal cancer? Duodecim; Laaketieteellinen Aikakauskirja 132(12): 1185-1193
Morales, A. 1978: Adjuvant immunotherapy in superficial bladder cancer National Cancer Institute Monograph 49: 315-319
Lin, J.C.; Cheng, J.Y.; Meng, C.L. 1992: An animal model for colon cancer metastases to the lung and establishment of metastatic cancer cell line Journal of the Formosan Medical Association 91(Suppl 1): S34-S38
Kan, N.; Imamura, M. 1993: Loco-regional immunotherapy with OK-432 and cultured autologous lymphocytes for patients with metastatic cancer Human Cell 6(2): 100-105
Negrier, S.; Douillard, J.-Y.; Gomez, F.éd.ér.; Lasset, C.; Chevreau, C.; Escudier, B. 2002: Interleukin-2 and interferon in metastatic kidney cancer. Experience of the French Immunotherapy Group Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 12(2): 213-218
Van der Meijden, A.P. 1992: New approaches to intravesical chemo-immunotherapy in superficial bladder cancer Progress in Clinical and Biological Research 378: 95-101
Schreinemachers, L.; Van der Meyden, A.; Steerenberg, P.; Feitz, W.; Groothuis, D.; De Jong, W.; Debruyne, F. 1987: BCG-RIVM: a new BCG preparation for intravesical immunotherapy of superficial bladder cancer Chemioterapia: International Journal of the Mediterranean Society of ChemoTherapy 6(2 Suppl): 713-716
Cao, M.; Ma, C.-k.; Ma, J.; Chen, H.-g.; Xue, W. 2011: Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer Zhonghua Zhong Liu Za Zhi 33(5): 385-387